Simpler Grants.gov #RFA-HL-26-017

NHLBI Catalyze Program Grant for Early-Stage Product Definition in HLBS Diseases

This opportunity from the National Institutes of Health (NIH), via the National Heart, Lung, and Blood Institute (NHLBI), invites applications for the Catalyze Program focused on early-stage product definition in heart, lung, blood, and sleep (HLBS) diseases. - Government Buyer: - National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute (NHLBI) - OEMs and Vendors: - No specific OEMs or vendors are named; this is a grant for research and development, not a procurement of commercial products. - Products/Services Requested: - Early-stage translational research for small molecules, biologics, and combination products - Focus on identifying and characterizing potential therapeutic candidates for HLBS diseases - No part numbers or quantities specified, as this is a research grant - Unique or Notable Requirements: - Open to a wide range of applicants: government entities, nonprofits, educational institutions, and businesses (including small businesses) - Designed to advance projects to meet entry criteria for the NHLBI Catalyze Preclinical Program - No direct procurement of goods or services; funding supports research activities only

Description

The NHLBI Catalyze Program aims to support the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing. This initiative focuses on early-stage translational support to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It is part of a suite of innovation grants designed to advance projects to meet entry criteria for the NHLBI Catalyze Preclinical Program. Eligible applicants include various government entities, nonprofits, educational institutions, and businesses, including small businesses.

View original listing